Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Co Enalapril · DIN 02291894 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19 Daily cost (source): $0.2647 Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Teva canada limited · schedule Prescription

DIN 02291894: Co Enalapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id COB Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2647; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291894 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77726 Therapeutic Notes (formulary) ** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.

Interchangeable products

Apo-Enalapril · DIN 02019892 · $0.2647 Enalapril · DIN 02400677 · $0.2647 Enalapril · DIN 02442973 · $0.2647 Jamp-Enalapril · DIN 02474808 · $0.2647 Mar-Enalapril · DIN 02444771 · $0.2647 Mylan-Enalapril · DIN 02300052 · $0.2647 Ran-Enalapril · DIN 02352257 · $0.2647 Ratio-Enalapril · DIN 02300001 · $0.2647 Sandoz Enalapril · DIN 02299968 · $0.2647 Taro-Enalapril · DIN 02300133 · $0.2647 Teva-Enalapril · DIN 02233006 · $0.2647 Vasotec · DIN 00670901 · $0.2647

Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291894

Shortage record checked 2026-09-13T08:10:21.292534+00:00